| Location: | Maryland |
|---|---|
| Posted: | Nov 15, 2024 |
| Due: | Nov 22, 2024 |
| Agency: | HEALTH AND HUMAN SERVICES, DEPARTMENT OF |
| Type of Government: | Federal |
| Category: |
|
| Solicitation No: | 75N95025Q00040 |
| Publication URL: | To access bid details, please log in. |
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
The National Center for Advancing Translational Sciences (NCATS) requires transcriptomics sequencing and analysis in liver spheroids. This requisition is requesting a contract to evaluate the RNA expression in liver toxicity associated with the systemic administration of antisense oligonucleotides (ASOs) in previously tested human, rat and mouse animal models. The project's phase one goal is to develop a predictive model of candidate ASO therapies' safety and acute toxicity. NCATS is seeking technical support to evaluate the safety and acute liver toxicity of candidate ASOs by checking the gene expression. The results from these studies, in conjunction with existing cell-based assays, will help better predict the safety of future candidate ASOs intended for clinical use. The objective of this contract is to generate proof-of-concept data for evaluating the ability of the 3D liver microtissue platform to predict the hepatoxicity of individual ASOs. If successful, this will represent a new means to screen ASOs for this type of toxicity that is cheaper, faster, and has high throughput. NCATS is seeking technical support to evaluate the safety and acute liver toxicity of candidate ASOs by checking the gene expression. The results from these studies, in conjunction with existing cell-based assays, will help better predict the safety of future candidate ASOs intended for clinical use.

With GovernmentContracts, you can:
...Follow Measuring mouse body composition Active Contract Opportunity Notice ID 75N98026Q00471...: * Rapid ...
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Bid Due: 6/09/2026
...Follow Renewal of licensing fee for the transgenic mouse strain, B-hIL2RA Active Contract... ...
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Bid Due: 6/08/2026
...of mouse embryos during in utero injection procedures. This capability is essential for ...
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Bid Due: 6/05/2026